Biocept, Inc.

BIOCQ

US09072V6002

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 09:58:15 15/07/2024 pm IST			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	-99.76%

26/04	Motion for Asset Sale Approved for Biocept, Inc.	CI
02/04	Motion for Asset Sale Approved for Biocept, Inc.	CI

Biocept Secures In-Network Provider Agreement with Blue Cross Blue Shield of Texas

January 10, 2017 at 08:06 pm IST

Biocept, Inc. announced that it has secured an in-network provider agreement with Blue Cross Blue Shield of Texas.

Latest news about Biocept, Inc.

Motion for Asset Sale Approved for Biocept, Inc.	26/04	CI
Motion for Asset Sale Approved for Biocept, Inc.	02/04	CI
Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index	24/23/24	CI
Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index	19/23/19	CI
Biocept, Inc. Filed for Bankruptcy	13/23/13	CI
Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer	21/23/21	CI
Sector Update: Health Care Stocks Slipping Late Friday8 Afternoon	09/23/09	MT
Sector Update: Health Care Stocks Slipping Friday Afternoon	08/23/08	MT
Sector Update: Health Care	08/23/08	MT
Biocept Signs Non-Exclusive Licensing Agreement With Plus Therapeutics on CNSide Tumor Cell Platform	08/23/08	MT
Wall Street Set to Open Flat Friday as Investors Remain Wary of Potential Interest Rate Hike	08/23/08	MT
Top Premarket Gainers	08/23/08	MT
Plus Therapeutics, Inc. Enters into License Agreement with Biocept for Cerebrospinal Fluid Tumor Cell Enumeration Assay	08/23/08	CI
Transcript : Biocept, Inc. - Special Call	31/23/31
Certain Warrants of Biocept, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2023.	24/23/24	CI
Certain Stock Options of Biocept, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2023.	24/23/24	CI
Certain Series A Convertible Preferred Stock of Biocept, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2023.	24/23/24	CI
Certain Common Stock of Biocept, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2023.	24/23/24	CI
Earnings Flash (BIOC) BIOCEPT Reports Q2 Revenue $589,000	15/23/15	MT
Biocept, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Biocept Says Board Chair Faye Wilson Died	14/23/14	MT
Biocept Names Antonino Morales as President, CEO	21/23/21	MT
Biocept, Inc. Appoints Antonino Morales as Chief Executive Officer	21/23/21	CI
Biocept, Inc. Announces Executive Changes	21/23/21	CI
Top Midday Decliners	25/23/25	MT

Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular technologies intended to aid medical professionals in CSF analysis and central nervous system (CNS) disease management in patients with solid tumors. It offers and conducts its commercialized diagnostic assays, which include cell capture and enumeration, immunocytochemistry, fluorescent in situ hybridization (FISH), and next generation sequencing (NGS). It has commercialized its CNSide assays for detecting and characterizing many different carcinomas and melanoma. These assays utilize its dual cellular and ctDNA technology platforms and provide biomarker analysis from a patientâs CSF sample.

Sector

Medical Equipment, Supplies & Distribution

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.0001

Average target price

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOCEPT, INC.	-99.76%	262
BIOMÉRIEUX	-7.11%	1.23TCr
LANTHEUS HOLDINGS, INC.	+98.69%	853.86Cr
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-22.31%	657.96Cr
DIASORIN S.P.A.	+7.25%	577.28Cr
AUTOBIO DIAGNOSTICS CO., LTD.	-23.61%	348.49Cr
ANDON HEALTH CO., LTD.	+5.84%	254.45Cr
MYRIAD GENETICS, INC.	+39.18%	241.11Cr
VITROLIFE AB	-7.70%	230.05Cr
10X GENOMICS, INC.	-69.05%	207.33Cr

Diagnostic & Testing Substances

Biocept, Inc.

Equities

BIOCQ

US09072V6002

Medical Equipment, Supplies & Distribution

Biocept Secures In-Network Provider Agreement with Blue Cross Blue Shield of Texas

Latest news about Biocept, Inc.

Chart Biocept, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

Quarterly earnings - Rate of surprise

Sector Diagnostic & Testing Substances